Arzeda and Amyris enter into joint development agreement for novel enzymes

In Washington, Arzeda, the Protein Design Company, entered into a joint development agreement with Amyris to design and develop novel enzymes for Amyris with unique functionalities, which Amyris will incorporate into their fermentation process to facilitate production of the target high value ingredients.

This marks the second joint project between the parties. Amyris and Arzeda collaborated successfully on a Defense Advanced Research Projects Agency (DARPA) Technology Investment Agreement (TIA) during the period of 2015 – 2019.

Funding of the project is milestone based, with Arzeda receiving an additional payment contingent on early success as well as a value-share on product commercialization. Enzymes being designed and developed by Arzeda for this project are not found in nature and thus represent the power of the computational platform to build enzymes with unique functionality without a natural starting point. Amyris and Arzeda expect to have fermentation strains containing enzymes designed by Arzeda developed during 2021.